A 50-year-old male patient treated with BV/gemcitabine for refractory stage IVB Hodgkin lymphoma experienced severe anaphylaxis requiring epinephrine during his second treatment cycle, later characterized as BV-induced IgE-mediated hypersensitivity by positive intradermal and basophil activation tests. This evidence concerns the gene IGHE and anaphylaxis.